NAD+ Training

Title	NAD+ Training
Acronym	NADIS_NAD+
Start date	2022-11-01
End date
Sponsor	Horizon Europe Framework Programme
Institution	German Center for Neurodegenerative Diseases
Principal investigator	Michela Deleidi E-Mail: michela.deleidi@dzne.de

Associated cell lines

• MPIi002-A (L1-1Mut, T4)
• MPIi003-A (IM2, L2-2Mut)
• MPIi003-A-1 (IM2GC, L2-2GC)

Project Description

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes that include the sirtuin family of protein deacylases, the poly(ADP-ribose) polymerases (PARPs) and the cyclic ADP-ribose (cADPr) synthases. Primary deficiencies of NAD+ homeostasis are the result of impaired biosynthesis, while secondary deficiencies can arise due to other factors affecting NAD+ homeostasis, such as increased NAD+ consumption or dietary deficiency of its vitamin B3 precursors. NAD+ depletion can manifest in a wide variety of pathological phenotypes, ranging from rare inherited defects to more common multifactorial, often age-related, diseases. In this project, we will investigate 1) how NAD+ homeostasis is regulated at different stages in life, (2) how its imbalance leads to disease at a systemic level and (3) which NAD+ repletion strategy is the most suitable to prevent or treat specific diseases.